concerta ritalin conversion chart

Serious - Use Alternative (1)lofepramine, methylphenidate. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (3)serdexmethylphenidate/dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Monitor BP. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Serious - Use Alternative (1)dihydroergotamine, methylphenidate. iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)levodopa, methylphenidate. Use Caution/Monitor. Monitor Closely (1)promethazine, methylphenidate. Use Caution/Monitor. Use Caution/Monitor. Monitor BP. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Currently on methylphenidate 5 mg BID or . CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Modify Therapy/Monitor Closely. Potential for additive CNS stimulation. Use Caution/Monitor. Use Caution/Monitor. Modify Therapy/Monitor Closely. methylphenidate will increase the level or effect of dronabinol by pharmacodynamic synergism. methylphenidate will decrease the level or effect of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Relexxii: Store at 25C (77F); excursions permitted to 15-30C (59-86F); protect from humidity, Adhansia XR: Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F); protect from light, Extended-release chewable (QuilliChew ER): Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F), Extended-release orally disintegrating (Cotempla XR-ODT): Store at 20-25C (68-77F); excursions permitted to 15-30C (59-86F); store in reusable travel case, Immediate-release (Ritalin): Store at 25C (77F); excursions permitted to 15-30C (59-86F); protect from light. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. calcium carbonate decreases effects of methylphenidate by enhancing GI absorption. Monitor Closely (1)methylphenidate, epinephrine inhaled. Interaction more likely in certain predisposed pts. Use Caution/Monitor. lansoprazole decreases effects of methylphenidate by enhancing GI absorption. Either increases toxicity of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Comment: Green tea may include caffeine. Modify Therapy/Monitor Closely. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)promazine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Monitor BP. Modify Therapy/Monitor Closely. Use Caution/Monitor. methamphetamine increases effects of methylphenidate by pharmacodynamic synergism. Mechanism: unknown. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. Other (see comment). Contraindicated. Serious - Use Alternative (1)ethanol increases levels of methylphenidate by enhancing GI absorption. Methylphenidate may diminish antihypertensive effects. Your list will be saved and can be edited at any time. Monitor for hypertension with concomitant use. Potential for additive CNS stimulation. Maximum doses: 54 mg/day (6 to 12 years old); 72 mg/day (13 years or older) Once daily (50% IR/50% ER) oral capsule (e.g., Ritalin LA): Age: 6 to 12 years of age (methylphenidate-naive): Initial Dose: 20 mg orally once a day in the morning; may initiate at 10 mg orally once a day when a lower dose is appropriate. Potential for additive CNS stimulation. Either increases effects of the other by serotonin levels. rotigotine, methylphenidate. Contraindicated. promethazine, methylphenidate. Monitor Closely (1)imipramine, methylphenidate. Methylphenidate may diminish antihypertensive effects. Serious - Use Alternative (1)ergotamine, methylphenidate. Use Caution/Monitor. methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Dosing recommendations are based on current dose regimen and clinical judgment. Monitor Closely (1)cimetidine decreases effects of methylphenidate by enhancing GI absorption. Contraindicated (1)rasagiline increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Other (see comment). Use Caution/Monitor. Other (see comment). Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. only. This drug is available at the lowest co-pay. Mechanism: pharmacodynamic synergism. The generic drug name of Concerta is methylphenidate. Methylphenidate may diminish antihypertensive effects. sodium zirconium cyclosilicate will increase the level or effect of methylphenidate by increasing gastric pH. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. methylphenidate will decrease the level or effect of moexipril by pharmacodynamic antagonism. Risk of acute hypertensive episode. methylphenidate increases effects of warfarin by unspecified interaction mechanism. Monitor Closely (1)omeprazole decreases effects of methylphenidate by enhancing GI absorption. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Contraindicated. Serious - Use Alternative (1)cabergoline, methylphenidate. By clicking send, you acknowledge that you have permission to email the recipient with this information. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)pirbuterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. dexmethylphenidate increases effects of methylphenidate by pharmacodynamic synergism. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Interaction more likely in certain predisposed pts. Methylphenidate may diminish antihypertensive effects. Contraindicated. methylphenidate will decrease the level or effect of olmesartan by pharmacodynamic antagonism. Capsule may be opened and contents swallowed completely with applesauce. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Monitor Closely (1)pimozide increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Modify Therapy/Monitor Closely. Use Caution/Monitor. Monitor Closely (1)cariprazine increases toxicity of methylphenidate by pharmacodynamic antagonism. caffeine increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)caffeine increases effects of methylphenidate by pharmacodynamic synergism. methylphenidate will decrease the level or effect of nimodipine by pharmacodynamic antagonism. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. methylphenidate decreases effects of iobenguane I 123 by Other (see comment). Risk of acute hypertensive episode. methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. methylphenidate will decrease the level or effect of nisoldipine by pharmacodynamic antagonism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. bromocriptine, methylphenidate. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Other (see comment). methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. Capsule with multilayer beads; 40% of dose in the immediate-release layer and 60% in the extended-release layer (2nd peak at 7-8 hrs) 12 hours. Methylphenidate may diminish antihypertensive effects. Monitor BP. Use Caution/Monitor. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. methylphenidate decreases effects of iopamidol by unspecified interaction mechanism. Contraindicated (1)benzphetamine increases effects of methylphenidate by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Additive vasospasm; risk of hypertension. Use Caution/Monitor. Risk of acute hypertensive episode. Amifampridine. Monitor BP. only. Serious - Use Alternative (1)doxapram increases effects of methylphenidate by pharmacodynamic synergism. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. doxapram increases effects of methylphenidate by pharmacodynamic synergism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Use Caution/Monitor. Interaction more likely in certain predisposed pts. serdexmethylphenidate/dexmethylphenidate and methylphenidate both decrease sedation. Potential for additive CNS stimulation. Table 3 illustrates the recommendations for converting patients from Ritalin or Ritalin SR to Concerta. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. A Patient Handout is not currently available for this monograph. Monitor Closely (1)nortriptyline, methylphenidate. only. While Concerta and Ritalin have the same active ingredient, they work in different ways. Methylphenidate is also the drug that manufacturers use in Ritalin. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. trimipramine, methylphenidate. Use Caution/Monitor. only. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Mechanism: pharmacodynamic synergism. Monitor Closely (1)aluminum hydroxide decreases effects of methylphenidate by enhancing GI absorption. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Minor (1)guarana increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Monitor BP. magnesium oxide decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. Contraindicated. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Applies only to extended release formulation nizatidine decreases effects of methylphenidate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Modify Therapy/Monitor Closely. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Share cases and questions with Physicians on Medscape consult. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. epinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Monitor Closely (1)methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. Either increases effects of the other by pharmacodynamic synergism. Monitor Closely (1)apomorphine, methylphenidate. Monitor Closely (1)isoproterenol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Risk of acute hypertensive episode. Risk of acute hypertensive episode. Your doctor may adjust your dose as needed. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor BP. Methylphenidate may diminish antihypertensive effects. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Risk of acute hypertensive episode. Potential for additive CNS stimulation. Monitor Closely (1)dobutamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Mechanism: unknown. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Potential for additive CNS stimulation. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Additive vasospasm; risk of hypertension. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. Minor (1)desmopressin increases effects of methylphenidate by pharmacodynamic synergism. Use Caution/Monitor. Monitor BP. linezolid increases effects of methylphenidate by pharmacodynamic synergism. Other (see comment). Risk of acute hypertensive episode. Avoid or Use Alternate Drug. Monitor Closely (1)methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Monitor Closely (1)pramipexole, methylphenidate. Sympathomimetics can antagonize the activity of some antihypertensive agents. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Potential for additive CNS stimulation.

Marc Newson Bibury Court, Articles C